SEC Form 4 · accession 0001209191-18-053866
Bionano Genomics, Inc. · BNGO
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Mark Borodkin
Officer — Chief Operating Officer
Period of report
Oct 1, 2018
Accepted (ET)
Oct 3, 2018 · 4:48 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001411690
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy)F1 | $7.77 | Oct 1, 2018 | A | 59,590 | A | — | Sep 30, 2028 | Common Stock | 59,590 | 59,590 | D |
Explanation of responses
- F125% of the shares subject to the stock option vest and become exercisable on October 1, 2018, and the remaining shares subject to the stock option vest and become exercisable in 36 equal monthly installments thereafter.